| IIEF-EF scores for placebo groups | IIEF-EF scores for intervention groups | ||||||
---|---|---|---|---|---|---|---|---|
ROB domain | No. of studies (no. of participants)* | Studies with low ROB (95% CI) (IV) | Studies with unclear or high ROB (95% CI) (IV) | Differencea(95% CI) | Between MA-homogeneity Q (P value) | Studies with low ROB (95% CI) (IV) | Studies with unclear or high ROB (95% CI) (IV) | Differenceb(95% CI) |
Summary 4 ROB-domains | 5 (1,202)/16 (3,006) | 1.92 (0.64 to 3.20) | 1.56 (0.93 to 2.20) | 0.33 (-0.96 to 1.62) | 20 (0.48) | 9.40 (6.96 to 11.83) | 8.33 (7.29 to 9.37) | -1.0 (-1.35 to 3.47) |
Allocation concealment | 13 (2,487)/48 (11,169) | 1.82 (1.14 to 2.50) | 1.75 (1.37 to 2.12) | 0.07 (-0.8 to 0.93) | 58 (0.88) | 9.10 (7.94 to 10.26) | 8.34 (7.63 to 9.05) | 0.78 (-0.65 to 2.20) |
Blinding participant | 42 (9,159)/19 (3,442) | 1.88 (1.45 to 2.31) | 1.43 (0.95 to 1.91) | 0.42 (-0.33 to 1.16) | 64 (0.35) | 8.39 (7.69 to 9.10) | 8.23 (7.28 to 9.19) | 0.16 (-1.02 to1.33) |
Blinding caregiver | 17 (3,652)/42 (8,652) | 1.94 (1.18 to 2.69) | 1.77 (1.40 to 2.15) | 0.17 (-0.61 to 0.96) | 56 (0.54) | 8.46 (6.92 to 10.01) | 8.64 (8.15 to 9.13) | -0.25 (-1.50 to 1.00) |
Blinding outcome assessor | 17 (3,278)/42 (9,659) | 1.82 (0.99 to 2.65) | 1.84 (1.48 to 2.21) | -0.02 (-0.83 to 0.79) | 57 (0.52) | 8.59 (7.15 to 10.03) | 8.43 (7.80 to 9.06) | 0.15 (-1.12 to 1.41) |